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Abstract Objectives: The present study was undertaken
to determine whether a single oral dose of menthol af-
fects the metabolism of caffeine, a cytochrome P450 1A2
(CYP1A2) substrate, and pharmacological responses to
caffeine in people.
Methods: Eleven healthy female subjects participated in
a randomized, double-blind, two-way crossover study,
comparing the kinetics and effects of a single oral dose of
caffeine (200 mg) in coffee taken together with a single
oral dose of menthol (100 mg) or placebo capsules. Ser-
um caffeine concentrations and cardiovascular and sub-
jective parameters were measured throughout the study.
Results: Co-administration of menthol resulted in an
increase of caffeine tmax values from 43.6±20.6 min
(mean±SD) to 76.4±28.0 min (P<0.05). The Cmax
values of caffeine were lower in the menthol phase than in
the placebo phase, but this effect was not statistically
significant (P=0.06). (AUC)0–24, (AUC)0–¥, terminal
half-life and oral clearance were not affected by menthol.
Only nine subjects’ cardiovascular data were included in
the analysis because of technical problems during the
measurements. After caffeine, heart rate decreased in
both treatment phases. The maximum decrease in heart
rate was less in the menthol phase ()8.9±3.9 beats/min)
than in the placebo phase ()13.1±2.1 beats/min)
(P=0.024). There were no statistically significant differ-
ences in systolic and diastolic blood pressures between
the two treatments.
Conclusions: We conclude that a single oral dose of pure
menthol (100 mg) delays caffeine absorption and blunts
the heart-rate slowing effect of caffeine, but does not affect
caffeine metabolism. The possibility that menthol slows
the absorption of other drugs should be considered.
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Introduction
Menthol (C10H20O) is a cyclic terpene alcohol, naturally
occurring in the volatile oils of various species of mentha
[1]. It has a pleasant odor and taste, and has been used
for many years in a wide variety of products ranging
from pharmaceutical preparations to flavor food,
toothpastes, confectionery, cigarettes and pesticides.
Peppermint oil (the major individual constituent of
which is menthol) has long been used as a carminative
for gastrointestinal symptoms [2]. Infusions or decoc-
tions of leaves from Mentha piperita are commonly used
in herbal remedies for the treatment of digestive disor-
ders in our country [3].
Despite widespread human exposure to menthol and
other monoterpenes found in essential oils, the effects of
these substances on xenobiotic metabolism are not well
characterized. Some of the terpenoids used in pharma-
ceutical preparations and as constituents of food induce
or inhibit drug metabolizing activities of liver in vitro.
Madyastha et al. demonstrated the ability of L-menthol
to induce the hepatic microsomal cytochrome P450 and
reduced nicotinamide adenine dinucleotide phosphate
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(NADPH)-cytochrome c reductase with oral adminis-
tration to rats [4]. A further study on the effects of
several terpenoid compounds on cytochorome P450 lev-
els in rat liver was carried out by Austin et al. In this
study, the induction of hepatic CYP2B subfamily after
in vivo treatment of rats with menthol was reported [5].
The inhibiting effects of menthol on rat liver CYP2B1
and CYP1A2 isoenzymes were described by De-Oliveira
et al. [6]. CYP1A2 inhibition was very weak in this in
vitro study. In recent studies, peppermint oil was re-
ported to inhibit CYP3A4 activity in rat and human
liver microsomes and to enhance the oral bioavailability
of the CYP3A4 substrate felodopine in people [7, 8].
Caffeine is one of the most widely and frequently
consumed xenobiotics throughout the world. Exposure to
caffeine occurs principally via diet, as well as pharma-
ceutical products. CYP1A2 mediates more than 95% of
caffeine metabolism. CYP1A2 is among the isoenzymes
with pronounced interindividual variation in activity
caused by constitutional and environmental factors [9].
In this present study, we hypothesized that the inges-
tion of menthol would modify the metabolism of caffeine.
If menthol inhibits caffeine metabolism, it would result in
decreased clearance and higher plasma levels of caffeine.
Therefore, subjects might experience increased cardio-
vascular and central nervous system side effects when
consuming caffeine. We used caffeine to study the effects
of menthol on drug metabolism—because of widespread
exposure of people to caffeine per se and its use as a
substrate probe for the investigation of CYP1A2 enzyme
activity [10]. The interaction between menthol and caf-
feine has not, to our knowledge, previously been studied
in man. Because of the potential for pharmacokinetic and
pharmacodynamic interactions and because co-admin-
istration of these two food constituents can be expected, a
study of the effect of menthol on the action of caffeine
was performed.
Materials and methods
Subjects
Eleven female subjects aged from 18 years to 50 years (mean±SD
29±9.7 years) were included in this study. Their body weight ran-
ged 50.0 kg to 62.0 kg (mean 53.7±3.3 kg) and their height ranged
150 cm to 170 cm (mean 161.7±4.9 cm). They were either fellows
of the Pharmacology Department of Dokuz Eylul University
Medical Faculty or their friends. Since we wanted to exclude the
effects of gender on CYP1A2 activity, female subjects were selected
[11]. The subjects were in good health on the basis of medical his-
tory, and routine biochemical and hematology testing. They were
non-smokers and were not taking medications, including oral con-
traceptives. During the study (2 days before and 24 h after the
procedure), the subjects were instructed to avoid any food or drink
containing caffeine or menthol. The study protocol was approved by
the Ethics Committee of Dokuz Eylul University Hospital, and each
subject gave her written informed consent before the study.
Chemicals
Caffeine and menthol were obtained from Sigma (Caffeine Anhy-
drous, Sigma-Aldrich Chemie Gmbh, Steinheim, Germany),
Mallinckrodt Baker (Menthol USP, Mallinckrodt Baker Inc. Paris,
Kentucky), respectively. Gelatin capsules were filled with an
appropriate dose of menthol or glucose (placebo) in the investi-
gator’s laboratory. Coffee was prepared by adding 200 mg anhy-
drous caffeine to decaffeinated instant coffee (Nescafe Classic,
decaffeinated, Nestle´ Espana S.A.) with 150 ml of water. Decaf-
feinated coffee (1.5 g; measured caffeine content 13.9±1.7 lg/ml)
was used per glass of coffee.
Study design
This was, a randomized, cross-over, double-blind study, with two
phases separated by at least 1-week washout period. After an
overnight fast, at 0800 hours, each subject consumed a single oral
dose of 100 mg menthol or placebo capsules with 100 ml of water
and 150 ml coffee containing 200 mg caffeine within 5 min.
Blood samples (8 ml each) were withdrawn through an
indwelling intravenous cannula before and 0.5, 1, 1.5, 2, 3, 4, 6, 8,
10 h after; and via venipuncture at 24 h after administration of
menthol or placebo capsules and coffee. Serum samples were sep-
arated by centrifugation at 2050 g for 15 min within 3 h of col-
lection. Aliquots of serum were stored at )20C until analysis of
caffeine concentrations.
Measurement of systolic and diastolic blood pressures (BP) and
heart rate (HR) were taken immediately before blood sampling. BP
and HR were measured using an automatic monitor (Patient
Monitor, GH Medical, USA). These cardiovascular measurements
were recorded at )15, )10, )5, 0, 10, 20, 30, 45, 60, 80, 90, 105 and
120 min after menthol or placebo capsules and coffee. Subjects
were kept fasting and in a supine position for the duration of the
120-min study. The morning baseline values were measured after
20 min of rest in the supine position.
The subjective effects were studied using an eight-item ques-
tionnaire. The questionnaire was given five times (at )10, 15, 40,
65, 80 min) during the first 120 min. The subjects were asked the
following questions: (1) how strong is the coffee? (2) how much do
you like the effect? (3) do you feel nauseated? (4) do you feel dizzy
or lightheaded? (5) do you feel stimulated? (6) do you feel heart-
burn or stomach discomfort? (7) do you feel flushing or warmth in
the skin? (8) do you feel fast heart beating or palpitations? The
questions were rated on a 10-cm visual analog scale with labeled 0
(not at all) and 10 (extremely).
Analytical chemistry
The extraction of caffeine from serum was carried out using a
previously described method by Jacob et al. [12]. Sample analysis
was performed using GC-MS (Hewlet Packard 6890 GC, 5973
MSD). High-performance capillary column (crosslinked 5% PH
ME siloxane), with dimensions of 30 m · 0.25 mm · 0.25 lm, was
used for separation. Injections (1 ll) were made in the splitless
mode with an injection port temperature of 250C, the carrier gas
(helium) flow rate was 1 ml/min and septum purge on-time was
1 min. The temperature programmed from 70C to 115C at
60C/min, then held for 4 min at 115C, from 115C to 150C at
7C/min and from 150C to 270C at 25C/min. The temperature
of the transfer line to the mass spectrometer was set at 280C.
Electron multiplier was programmed to carry out analysis at 200 V
above the autotune value. Ionization was in the electron impact
(EI) mode at 70 eV. 1,3-(15 N)-2-(13C)-Caffeine was used as an
internal standard (a gift from Dr Peyton Jacob, Clinical Pharma-
cology Laboratory, University of California, SF).
Calibration was performed with aqueous solution at concen-
trations 0, 500, 1000, 2000, 3000, 4000 and 5000 ng/ml for caffeine.
The internal standard concentration was 1000 ng/ml. The rela-
tionship between response and analyte concentration was linear in
the considered calibration range (r2=1). The ions (m/z) used for
quantification were 194 for caffeine and 197 for internal standard
with retention time of 13.40 min. The lower limit of quantification
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for caffeine was 10 ng/ml. The interday coefficient of variation for
standard aqueous solution of caffeine concentration at 2000 ng/ml
was 6.1% (n=36). The intraday coefficients of variations for
standard aqueous solution of caffeine concentrations at 500, 2000,
5000 ng/ml were 4.5%; 3.7% and 6.2%; respectively (n=5). Each
plasma sample was measured in duplicate. The respective mean
values were used for further calculations.
The assay was controlled for possible physicochemical inter-
action of caffeine with menthol and decaffeinated coffee. For this
purpose, an in vitro study was conducted. Briefly, 1.33 mg caffeine
dissolved in 10 ml water was mixed with 0.66 mg menthol, 10 mg
decaffeinated coffee or both. The samples were visually inspected
and analyzed for caffeine by the above-described GC-MS method.
Data analysis
Caffeine kinetics were characterized by the area under the plasma
concentration–time curve (AUC)0–24, and (AUC)0–¥, peak con-
centration in serum (Cmax), time to reach Cmax (tmax), and terminal
half-life (t1/2). Cmax and tmax were determined from the actual
measurements. The elimination rate constant ke was estimated
using at least four data points of the terminal phase (from 4 h to
24 h) of the log serum caffeine concentration–time curve. The
elimination half-life was obtained from t1/2=0.693/ke. (AUC)0–24
and (AUC)0–¥ were calculated using the trapezoidal rule. (AUC)0–¥
was estimated by the addition of the residual area beyond the
sampling time of the last measurable concentration. The residual
area was calculated from integration on the basis of the regression
slope of terminal elimination phase. The oral clearance (CLoral) of
caffeine was calculated as the dose divided by the (AUC)0–¥.
Individual time profiles of cardiovascular effects were calculated
on the basis of change from the morning baseline value. The effect
area during the first 120 min following menthol/placebo capsule
and coffee ingestion, (AUEC)0–120, was calculated using the linear
trapezoidal method.
Statistical analysis
Differences in pharmacokinetic and pharmacodynamic parameters
for caffeine after co-administration with menthol or placebo cap-
sule were analyzed by the paired Student t-test. In addition, to
examine drug reactions as a bioequivalence problem, the ratio of
pharmacokinetic parameters in the menthol relative to placebo
conditions was determined, along with the 95% confidence inter-
vals [13]. Cardiovascular data and subjective questionnaire at
various times were analyzed by repeated-measures ANOVA. Sta-
tistical calculations were performed using the Instat program
(GraphPAD Software, San Diego, CA, USA). The differences were
considered statistically significant when P was <0.05. Data are
presented as mean values with SD.
Results
Serum caffeine concentration–time curves were plotted
for each subject, and pharmacokinetic parameters were
calculated. The mean serum concentration–time profiles
after ingestion of 200 mg caffeine with menthol or pla-
cebo capsules are shown in Fig. 1. The (AUC)0–24 and
(AUC)0–¥ values of caffeine were not significantly dif-
ferent during the menthol and placebo phases. Menthol
had a highly significant effect on caffeine tmax. Caffeine
tmax value was 1.8-fold longer during menthol phase.
The Cmax values of caffeine were lower during menthol
phase than placebo phase, but the difference was not
significant (P=0.065). However, serum levels of caffeine
were significantly lower at 0.5 h (P=0.003) and 1.0 h
(P=0.02) during the menthol than the placebo phase.
Pharmacokinetic parameters of caffeine are summarized
in Table 1. The ratios of menthol/placebo values for
selected pharmacokinetic parameters with 95% confi-
dence intervals are as follows: tmax=1.19 (95% CI 1.37–
2.44); Cmax=0.95 (0.90–1.00); t1/2=1.05 (0.84–1.26);
and AUC0–24=0.95 (0.85–1.05). The 95% confidence
intervals of the ratios of tmax in the menthol versus
placebo condition did not overlap 1.0, consistent with
the findings of significant difference with the paired
t-test. Analysis of plasma samples taken just before
caffeine administration (0 h) verified the absence of
residual caffeine. This indicates that there were no car-
ryover effects of caffeine.
Cardiovascular data from nine subjects were ana-
lyzed because the cardiovascular data of two subjects
were lost due to technical reasons. The average baseline
HR was 74 beats/min in the placebo phase and 70 beats/
min in the menthol phase (NS). After caffeine, HR
decreased in both treatment phases. The maximum
decrease in HR was less in the menthol phase
Fig. 1 Mean (SD) serum
caffeine concentration–time
curve, after 200 mg caffeine in
coffee in the presence of 100 mg
menthol or placebo. Placebo
circles, menthol squares
(n=11). *Phase difference
P<0.05, caffeine with menthol
versus caffeine with placebo at
0.5 h and 1 h
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()8.9±3.9 beats/min) than in the placebo phase
()13.1±2.1 beats/min; P=0.024). The maximal changes
were recorded at 37.2±19.5 min in the menthol phase
and at 43.9±33 min in the placebo phase. The mean
change in HR between two phases was statistically sig-
nificant at 10 min. There was no significant difference
between area under the Dheart rate–time response curves
for the two treatments. The mean systolic BPs at base-
line were 111.2 mmHg in the placebo phase and
111.1 mmHg in the menthol phase; and the mean dia-
stolic BPs were 67.5 mmHg in the placebo phase and
66.3 mmHg in the menthol phase. There were no sig-
nificant differences in blood pressures and area under the
Dblood pressure–time response curves for the two
treatments. Figure 2A shows the mean HR change;
Fig 2B shows the mean systolic BP change; Fig 2C
shows the mean diastolic BP change.
Subjects reported significantly more heartburn or
stomach discomfort with menthol capsule than with
placebo capsule on the 15th, 40th and 65th minutes
(P=0.0156). There were no significant differences in
other subjective reports comparing menthol and placebo
phases.
In vitro, there was no dissolution problem of caffeine
when menthol or decaffeinated coffee or both of them
were added to the solution. Caffeine concentrations were
similar within the three groups.
Discussion
The present study was undertaken to determine whether
menthol affects the metabolism of and/or pharmaco-
logical responses to caffeine in people. Because of the
potential for pharmacokinetic interactions between die-
tary caffeine and medications, many studies have
addressed this problem. However, we are unaware of
other studies of interactions between food and caffeine.
Menthol is used in a wide range of products, as well as
for medicinal purposes [2].
Menthol is highly lipid soluble and is rapidly
absorbed from the small intestine when taken orally. We
chose to use a 100-mg menthol dose in this study be-
cause, in our previous study, we had determined the
disposition kinetics of this dose of menthol [14]. It was a
safe dose for the subjects and was not so large as to be
irrelevant with respect to exposure in the diet.
Oral absorption of caffeine is rapid and complete [9].
In humans, peak plasma concentrations of caffeine are
observed approximately 30–60 min after oral consump-
tion, although the range can be as wide as 15–120 min
because of variations in gastric emptying [15]. The tmax
value after 100 mg menthol averaged 61±26 min (range
30–120 min) [14] and was close to caffeine’s tmax value.
In the present study, co-administration of menthol
caused a significant increase in caffeine tmax and slight
decrease of caffeine Cmax, but did not affect t1/2. These
findings suggested that the effect of menthol is primarily
to slow caffeine absorption.
Peppermint oil and menthol are carminative and
gastric sedative, which relax gastrointestinal muscle both
in vitro and in vivo [16, 17, 18, 19]. Using a receptor
binding assay, Hawthorn et al. [20] demonstrated com-
petitive antagonism with L-menthol of [3H]-nitrendipine
and the dihydropyridine radioligand [3H]-(+)-PN200–
110 binding to cardiac, neuronal and intestinal smooth
muscle. L-Menthol’s effect was more potent in intestinal
smooth muscle than cardiac muscle and neuronal
preparations. These data suggest that menthol acts by
reducing the availability of calcium in gastrointestinal
smooth muscle. The relaxant effect of menthol on the
gastrointestinal tract could influence the rate of drug
Table 1 The pharmacokinetic parameters of caffeine (single oral
dose, 200 mg) in combination with either menthol (M; single oral
dose, 100 mg) or placebo capsule (P) in 11 female subjects. tmax
time after dosing to maximum serum concentration, Cmax maxi-
mum serum concentration achieved after a single oral dose, t1/2
elimination half-life, AUC area under the serum concentration
versus time curve, CL/F oral clearance
Subject no tmax (min) Cmax (lg/ml) t1/2 (h) AUC(0–24) (lg min/ml) AUC(0–¥) (lg min/ml) CL/F (ml/min kg)
P M P M P M P M P M P M
1 60 90 6.30 5.90 6.06 7.62 3587.8 3988.7 3849.9 4516.2 0.96 0.82
2 30 60 6.10 6.18 3.42 4.36 2870.8 2644.9 2900.3 2715.4 1.30 1.39
3 30 60 5.75 5.45 2.89 3.66 1906.4 2127.8 1920.4 2157.9 1.93 1.72
4 30 90 6.90 5.91 4.54 4.31 2662.0 2708.1 2740.7 2777.2 1.40 1.38
5 60 90 5.60 5.05 2.77 3.78 2430.3 2068.2 2438.8 2096.9 1.58 1.83
6 30 90 6.50 5.36 4.75 3.74 2524.8 2374.2 2609.1 2410.6 1.24 1.34
7 30 30 6.34 6.24 3.44 5.24 3081.2 3352.5 3113.4 3521.7 1.26 1.11
8 30 90 6.72 6.71 8.65 7.20 5422.5 4268.4 6445.5 4767.1 0.54 0.74
9 30 30 6.24 6.60 4.07 4.26 2587.5 2532.0 2642.2 2591.8 1.43 1.46
10 60 120 6.08 5.56 5.10 3.03 3603.5 2712.2 3770.9 2728.8 0.98 1.38
11 90 90 6.60 6.85 5.38 3.32 4269.9 3717.7 4504.2 3749.9 0.89 1.07
Mean 43.6* 76.4 6.28 5.98 4.64 4.59 3176.9 2954.1 3357.7 3093.9 1.23 1.29
SD 20.6 28.0 0.39 0.59 1.7 1.5 995.0 757.4 1260.7 916.6 0.37 0.34
*Phase difference P<0.05, caffeine with menthol versus caffeine with placebo
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absorption by decreasing gastric emptying, which most
likely accounts for the slowing of caffeine absorption in
our study.
We obtained tmax and Cmax values from the serum
concentration–time curves. We took the blood samples
every half-an-hour around the expected Cmax of caffeine.
Thus, we may have missed the actual peak. In vitro, the
solubility of caffeine did not decrease when menthol
and/or decaffeinated coffee was added. Therefore, al-
tered solubility appears not to be responsible for the
apparent delay in absorption of caffeine.
Studies in laboratory animals have found that a
number of terpenoids and essential oils, many of which
are used in pharmaceutical preparations and as con-
stituents of food, induce drug-metabolizing activities of
the liver and thus could modify pharmacological re-
sponses to various drugs [5]. Oral administration of
L-menthol to rats (800 mg/kg per day, for up to 7 days)
induces the liver microsomal enzymes cytochrome P450
and NADPH-cytochrome c reductase [5]. Similar
observations have been made for pulegone and 1,8-
cineol, in which exposure of rats to these compounds
resulted in induction in the levels of cytochrome P450 [21,
22]. De-Olivera et al. [6] showed the weak inhibitory
effect of menthol on methoxyresorufin-O-demethylase
(MROD, CYP1A2) activity. In their study, 40 lM
menthol decreased rate of O-dealkylation by 20%.
However, this in vitro finding may not be extrapolated
to in vivo results, because menthol is rapidly but
incompletely metabolized to menthol glucuronide
in vivo and the remainder of menthol is metabolized by
hydroxylation [23, 24]. When human subjects were given
oral doses of 100 mg menthol, only menthol glucuronide
was detected in their plasma [14]. The major pathway in
caffeine metabolism is N-demethylation, which is carried
out by CYP1A2. Measures of caffeine N-demethylation
have been used to asses hepatic CYP1A2 activity [25].
A limitation of this study is that ratios of metabolites of
caffeine in urine were not measured. However, correla-
tion between several urine metabolite ratios reflecting
CYP1A2 activity and the clearance of caffeine have been
observed [25]. We calculated oral clearance of caffeine,
which reflects change in metabolism and did not find any
difference between menthol and placebo phases. So, we
conclude that ingestion of single, 100 mg menthol does
not affect caffeine metabolism.
In doses typically found in two cups of coffee, caffeine
causes a slight decrease in heart rate with an increase in
blood pressure and systemic release of epinephrine,
norepinephrine and renin [9, 26, 27, 28]. Caffeine chan-
ged blood pressure and heart rate slightly in our study.
The maximal decrease in heart rate after caffeine was
Fig. 2 Changes in heart rate
(A), systolic blood pressure (B)
and diastolic blood pressure (C)
plotted over time after 200 mg
caffeine in coffee in the presence
of 100 mg menthol or placebo.
Data points represent the mean
(SD). Placebo circles, menthol
squares (n=9). *Phase
difference P<0.05, caffeine
with menthol versus caffeine
with placebo at 10 min
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significantly less in the presence of menthol. We believe
that this effect of menthol can be explained in two ways:
(1) menthol’s effect on lowering serum caffeine levels
during the absorption phase, as evidenced by this cur-
rent study and (2) menthol’s effect on increasing heart
rate as shown in our previous study [14]. The effect of
menthol to increase heart rate does not appear to be a
reflex response to systemic vasodilation, since blood
pressure was not lowered by menthol. The mechanism
by which menthol increases heart rate has not yet been
established. Of note is that Pritchard et al. [29] have
found that denicotinized menthol smokers had a greater
increase in heart rate following smoking than did de-
nicotinized non-menthol smokers, supporting the idea
that menthol increases heart rate.
In conclusion, we found that pure menthol (single
dose administration, 100 mg) delays caffeine absorption
and blunts the heart-rate slowing effect of caffeine, but
does not affect caffeine metabolism. Further research is
required to see whether repeated doses of menthol would
affect caffeine metabolism. The possibility that menthol
slows the absorption of other drugs should be consid-
ered.
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